openPR Logo
Press release

Global Rheumatic Disorders Drug Market Size, Share, Analysis, Industry Report and Forecast 2021-2027

01-15-2022 06:45 AM CET | Health & Medicine

Press release from: Orion Market Research

The global rheumatic disorders drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Rheumatic disorders are a wide range of conditions that are characterized by chronic pain, with some of the most common conditions being osteoarthritis (OA) and rheumatoid arthritis (RA), and it is estimated that about one in four adults in America is diagnosed with a rheumatic disorder. The rheumatic disorder therapy area is multi-disciplinary and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion.

The majority of rheumatic disorders are treated using largely genericized pain management drugs. The incidence of many indications within the rheumatic disorders therapy area continues to rise and as the global population ages prevalence will increase which is a key driver of market growth. The market growth will also be driven by the entry of new products to the market, with two drug classes, in particular, driving the strong market growth.

To Request a Sample of our Report on Global Rheumatic Disorders Drug Market: https://www.omrglobal.com/request-sample/rheumatic-disorders-drug-market

The global rheumatic disorders drug market analysis includes some of the key market players such as AbbVie Inc, Amgen Inc., Johnson & Johnson Services Inc., Novartis International AG, among others. To maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships and collaborations, and mergers and acquisitions. For instance, in November 2021, Sandoz Egypt, in collaboration with the Egyptian Orthopedic Association (EOA), has announced the launch of a new non-steroidal anti-inflammatory drug (NSAID from Sandoz), etoricoxib, for the treatment of arthritis and chronic rheumatic disorders symptoms.

Market Coverage

· The market number available for – 2020-2027

· Base year- 2020

· Forecast period- 2021-2027

· Segment Covered

· Regions Covered- Globally

· Competitive Landscape: AbbVie Inc, Amgen Inc., Johnson & Johnson Services Inc., Novartis International AG, among others.

(Get 15% Discount on Buying this Report)

A full Report of Global Rheumatic Disorders Drug Market is Available at: https://www.omrglobal.com/industry-reports/rheumatic-disorders-drug-market

Global Rheumatic Disorders Drug Market Report Segmentation

By Route of Administration

• Oral

• Parenteral

By Drug Class

• Disease-modifying Anti-rheumatic Drugs (DMARDs)

• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

• Corticosteroids

• Uric Acid Drugs

• Others

Global Rheumatic Disorders Drug Market by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

Reasons to buy from us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Rheumatic Disorders Drug Market Size, Share, Analysis, Industry Report and Forecast 2021-2027 here

News-ID: 2527852 • Views:

More Releases from Orion Market Research

Microfinance Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031
Microfinance Market Size, Trends, Latest Insights, Analysis and Forecast 2024-20 …
The global microfinance market is anticipated to grow at a considerable CAGR of around 14.8% during the forecast period (2024-2031). The market growth is driven by the rising demand for finance among the low-income and more overlooked sections of society, government support, and the continuous establishment of microfinance institutions across the globe. The World Bank estimated that over 7,000 microfinance institutions are operating across the globe, serving nearly 16 million
Oral and Dental Probiotics Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031
Oral and Dental Probiotics Market Size, Trends, Latest Insights, Analysis and Fo …
The global oral and dental probiotics market is anticipated to grow at a CAGR of 8.5% during the forecast period (2024-2031). The market growth is driven by the rising awareness about the oral health benefits associated with oral and dental probiotics. The industry growth is also driven by the increasing popularity of combination products, which integrate probiotics with other oral health-enhancing ingredients. Additionally, the rising preference for natural and preventive
Wireless Health Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031
Wireless Health Market Size, Trends, Latest Insights, Analysis and Forecast 2024 …
The global wireless health market is anticipated to grow at a significant CAGR of approx. 22.3% during the forecast period (2024-2031). The market growth is driven by the increase demand for chronic disease management solutions, fitness tracking, supporting medication adherence, hampering hospital readmissions, symptom tracking, and managing mental & behavioral health. Additionally, the evolution of healthcare IT is also contributing to market growth through the integration of the Internet of
Antiallergic Non-Drug Supplement Market Will Exhibit an Impressive Expansion by 2024-2031 | General Nutrition Center Holdings, LLC (GNC), Emerald Laboratories
Antiallergic Non-Drug Supplement Market Will Exhibit an Impressive Expansion by …
Antiallergic Non-Drug Supplement Market is anticipated to grow at a significant CAGR during the forecast period. An antiallergic non-drug supplement is a medicinal product that includes various types of nutritional supplements, oils, among others. These supplements are categorized into tablets, capsules, and liquid dosage forms. Antiallergic non-drug supplements can alleviate various types of allergic symptoms and enable allergic patients to deal with the allergic symptoms without using any chemical-based formulations

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug